Serena Borrelli, MD, Université catholique de Louvain & Hôpital Erasme, Université Libre de Brussels, Brussels, Belgium, discusses her research into the performance of advanced MRI biomarkers for multiple sclerosis (MS) diagnosis. While early diagnosis and treatment is possible with the current diagnostic criteria, specificity is not very high and there is a risk of misdiagnosis. Dr Borrelli’s research focused on MRI biomarkers, specifically the central vein sign (CVS), paramagnetic rim lesions (PRL), and cortical lesions (CL). The study analyzed their diagnostic performance, alone and in combination, and their association with clinical outcomes. CVS had the best performance in terms of distinguishing MS from non-MS cases, but combination of the three performed better than each biomarker alone. PRL and CL correlated with MS severity and disability scale, while CVS did not. PRL at baseline was also predictive of progression independent relapse activity (PIRA) over two years. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть